.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX12_Tafasitamab.Tafasitamab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX12_Tafasitamab.Tafasitamab| name: | Tafasitamab |
| ATC code: | L01FX12 | route: | intravenous |
| n-compartments | 2 |
Tafasitamab is a humanized monoclonal antibody targeting CD19, used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is FDA approved for this indication.
Pharmacokinetic parameters reported for patients with relapsed or refractory DLBCL receiving tafasitamab intravenously. PK parameters are for adult patients as described in registration trials and FDA/EMA assessment reports.
Hoy, SM (2020). Tafasitamab: First Approval. Drugs 80(16) 1731–1737. DOI:10.1007/s40265-020-01405-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/32946059